Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K Current Report, dated March 20, 2026, details significant corporate governance changes for Damora Therapeutics, Inc. (Nasdaq: DMRA), a biopharmaceutical company. The report focuses on the appointment of a new Chief Executive Officer, changes to the Board of Directors, and updated executive compensation arrangements effective in late March 2026.

Key Financial Metrics and Compensation

The filing does not provide revenue, profit, cash flow, or debt metrics. Financial data is limited to executive compensation terms:

  • CEO Base Salary: $695,000 annually for Jennifer Jarrett.
  • CEO Target Bonus: 55% of base salary.
  • CEO Equity Grant: 500,000 Restricted Stock Units (RSUs) and options to purchase 1,500,000 shares.
  • General Counsel Base Salary: $440,000 annually for Garrett Winslow.
  • General Counsel Target Bonus: 40% of base salary.
  • General Counsel Equity Grant: Options to purchase 250,000 shares.
  • Director Equity Grant: Options to purchase the lesser of 40,000 shares or a value-based calculation for new directors.

Material Changes Versus Prior Period

The filing reports the following material changes in leadership and governance:

  • CEO Appointment: Jennifer Jarrett appointed President and CEO, effective March 30, 2026, succeeding Sherwin Sattarzadeh.
  • COO Transition: Sherwin Sattarzadeh transitions from CEO to Chief Operating Officer.
  • Board Resignations: Amit Munshi, Carl Goldfischer, and Jayson Dallas resigned from the Board effective March 23, 2026, with full acceleration of their equity awards.
  • Board Appointments: Jennifer Jarrett appointed as a Class II director; Michael Landsittel and Cameron Turtle appointed as Class III directors effective March 23, 2026.
  • Board Size Reduction: The Board size decreased from seven to six members.
  • Committee Leadership: Peter Harwin appointed Chair of the Board; Michael Landsittel appointed Chair of the Audit Committee.

Outlook, Risks, and Contingencies

Management Commentary: The Board cited Ms. Jarrett's extensive experience in biopharmaceutical operations and investment banking, as well as the new directors' expertise in finance and clinical development, as key qualifications for their appointments.

Severance and Change in Control:

  • CEO: In a Change in Control (CIC) scenario, Ms. Jarrett is eligible for 18 months of base salary, a lump-sum target bonus, and accelerated vesting of all equity awards. Outside a CIC window, severance is 12 months of base salary with partial equity acceleration.
  • General Counsel: In a CIC scenario, Mr. Winslow is eligible for 12 months of base salary and accelerated vesting of all equity awards. Outside a CIC window, severance is 12 months of base salary without equity acceleration.

Risks: The filing notes that the resignations of the three directors were not the result of any disagreements with the Company regarding operations, policies, or practices.

Investor Verification Checklist

  • Verify the effective date of Jennifer Jarrett's CEO appointment (March 30, 2026) and the transition of Sherwin Sattarzadeh to COO.
  • Confirm the full acceleration of equity awards for the three resigning directors (Munshi, Goldfischer, Dallas) and the specific vesting schedules for new equity grants.
  • Review the attached Offer Letters (Exhibits 10.1 and 10.2) for complete terms regarding severance, bonuses, and equity vesting conditions.
  • Assess the impact of the reduced Board size (from 7 to 6) on committee composition and governance oversight.
  • Monitor the press release (Exhibit 99.1) for additional strategic context regarding the leadership changes.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.